Drug – bio-affecting and body treating compositions – Lymphokine
Reexamination Certificate
2005-02-08
2005-02-08
Kemmerer, Elizabeth (Department: 1647)
Drug, bio-affecting and body treating compositions
Lymphokine
C424S198100, C514S002600, C514S012200, C530S300000, C530S350000, C530S351000, C530S399000
Reexamination Certificate
active
06852313
ABSTRACT:
Novel stem cell factors, oligonucleotides encoding the same, and methods of production, are disclosed. Pharmaceutical compositions and methods of treating disorders involving blood cells are also disclosed.
REFERENCES:
patent: 3898837 (1975-08-01), Boege
patent: 4275056 (1981-06-01), Takaku et al.
patent: 4338397 (1982-07-01), Gilbert et al.
patent: 4353242 (1982-10-01), Harris et al.
patent: 4438032 (1984-03-01), Golde et al.
patent: 4634665 (1987-01-01), Axel et al.
patent: 4695542 (1987-09-01), Yokota et al.
patent: 4703008 (1987-10-01), Lin
patent: 4714680 (1987-12-01), Civin
patent: 4721096 (1988-01-01), Naughton et al.
patent: 4722998 (1988-02-01), Cantor et al.
patent: 4808611 (1989-02-01), Cosman
patent: 4810643 (1989-03-01), Souza
patent: 4845078 (1989-07-01), Masaoka
patent: 4847325 (1989-07-01), Shadle et al.
patent: 4877729 (1989-10-01), Clark et al.
patent: 4879227 (1989-11-01), Clark et al.
patent: 4959314 (1990-09-01), Mark et al.
patent: 4959455 (1990-09-01), Clark et al.
patent: 4965204 (1990-10-01), Civin
patent: 5087570 (1992-02-01), Weissman et al.
patent: 5119315 (1992-06-01), Kemp et al.
patent: 5121337 (1992-06-01), Brown
patent: 5599703 (1997-02-01), Davis et al.
patent: 5620685 (1997-04-01), Nishi et al.
patent: 5641670 (1997-06-01), Treco et al.
patent: 5767074 (1998-06-01), Besmer et al.
patent: 5772992 (1998-06-01), Bauer et al.
patent: 5786323 (1998-07-01), Nakahata
patent: 5935565 (1999-08-01), Besmer et al.
patent: 0 232 707 (1987-08-01), None
patent: 0 845 268 (1998-06-01), None
patent: 62-223126 (1987-10-01), None
patent: 8325294 (1996-12-01), None
patent: 62-107796 (1997-05-01), None
patent: 09154578 (1997-06-01), None
patent: WO 8904452 (1989-05-01), None
patent: WO 9203459 (1992-03-01), None
patent: WO 9207074 (1992-04-01), None
patent: WO 9321936 (1993-11-01), None
patent: WO 9506112 (1995-03-01), None
patent: WO 9528479 (1995-10-01), None
patent: WO 9818924 (1998-05-01), None
patent: WO 9823773 (1998-06-01), None
Skolnick et al. From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends in Biotech 18(1): 34-39, 2000.*
Bork, A. Powers and pitfalls in sequence analysis: the 70% hurdle. Genome Res 10: 398-400, 2000.*
Doerks et al. Protein annotation: detective work for function prediction. Trends in Genetics 14(6): 248-250, 1998.*
Smith et al. The challenges of genome sequence annotation or “The devil is in the details”, Nature Biotech 15: 1222-1223, 1997.*
Brenner, S.E. Errors in genome function. Trends in Genetics 15(4): 132-133, 1999.*
Bork et al. Go hunting in sequence database but watch out for the traps. Trends in Genetics. 12(10): 425-427, 1996.*
Wells. J.A. Additivity of mutational effects in proteins. Biochemistry 29 (37): 8509-8517, 1990.*
Ngo et al. Computational complexity, protein structure prediction, and the Levinthal paradox. The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495, 1994.*
Pettit et al. The development of site-speicifc drug delivery systems for protein and peptide biopharmaceuticals. Trends in Biotech 16: 343-349, 1998.*
Longley BJ, Carter EL. SCF-KIT pathway in human epidermal melanocyte homeostasis. J Invest Dermatol. 113(1):139-140, 1999.*
Sieberblum M. Growth factor synergism and antagonism in early neural creast development. Biochemistry and Cell Biology-Biochimie et biologie cellulaire 76(6): 1039-1050, 1998.*
Vancoillie G, Lambert J. Nayaert JM. Melanocyte biology and its implications for the clinician. Eur J Dermatol. 9(3):241-51, 1999.*
Nishikawa et al. In utero manipulation of coat color formation by a monoclonal anti-c-kit antibody: two distinct waves c-kit dependency during melanocyte development. EMBO J 10(8): 2111-2118, 1991.*
Spritz RA. Piebaldism, Waardenburg syndrome, and related disorders of melanocyte development. Semin Cutan Med Surg. 16(1):15-23, 1997.*
Morrison-Graham K, Weston JA. Transient steel factor dependence by neural crest-derived melanocyte precursors. Dev Biol. 159(1):346-352, 1993.*
Murphy M, Reid K, Williams DE, Lyman SD, Bartlett PF. Steel factor is required for maintenance, but not differentiation, of melanocyte precursors in the neural crest. Dev Biol. 153(2):396-401, 1992.*
MacKenzie et al. Activation of the receptor tyrosine kinse kit is required for the proliferation of melanoblasts in the mouse embryo. Develop Biol 192: 99-107, 1997.*
Grichnik et al. The SCF/KIT pathway plays a critical role in the control of normal human melanocyte homeostasis. J Invest Dermatol 111: 233-238, 1998.*
Costa et al. Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. J Exp Med. 183(6):2681-2686, 1996.*
Giebel et al. Mutation of the KIT (mast/stem cell growth factor receptor) protooncogene in human piebaldism. Proc Natl Acad Sci U S A. 88(19):8696-8699, 1991.*
Kawakami et al. Transforming growth factor beta1 regulates melanocyte proliferation and differentiation in mouse neural crest cells via stem cell factor/KIT signaling. J Invest Dermatol. 118(3):471-478, 2002.*
Norris et al. The expression of the c-kit receptor by epidermal melanocytes may be reduced in vitlligo. Br J Dermatol. 134(2):299-306, 1996.*
Wilkie et al. Neural crest progenitors of the melanocyte lineage: coat colour patterns revisited. Development. 129(14):3349-3357, 2002.*
Bodine et al., “Combination of Interleukins 3 and 6 Preserves Stem Cell Function in Culture and Enhances Retrovirus-Mediated Gene Transfer Into Hematopoietic Stem Cells,”Proc. Nat'l Acad. Sci., USA, 86:8897-8901 (1989).
Boswell et al., “A Novel Mast Cell Growth Factor (MCGF-3) Produced by Marrow-adherent Cells that Synergizes with Interleukin 3 and Interleukin 4,” Exp. Hermatol., 18:794-800 (1990).
Bowie et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,”Science, 247:1306-1310 (1990).
Broxmeyer et al., “Cell-Free Granulocyte Colony Inhibiting Activity Derived from Human Polymorphonuclear Neutrophils,”Exp. Hemat.,5:87-102 (1977).
Dexter, T.M., “Haemopoietic Growth Factors,” I, 45(2):337-349 (1989).
Dick et al., “Introduction of New Genes into Hematopoietic Stem Cells,”J. Cell. Biol.,Supplement 11A, p. 187 (1987) (Abstract D 026).
Dick et al., “Introduction of Selectable Gene into Primitive Stem Cells Capable of Long-Term Reconstitution of the Hemopoietic System of W/W Mice,”Cell, 42:71-79 (1985).
Frömmel et al., “An Estimate of the Effect of Point Mutation and Natural Selection on the Rate of Amino acid Replacement in Proteins,”J. Mol. Evol.,21:233-257 (1985).
Fung et al., “Molecular cloning of cDNA for murine interleukin-3,”Nature, 307:223-237 (1984).
Gough et al., “Molecular Cloning of cDNA Encoding a Murine Haematopoietic Growth Regulator, Granulocyte-Macrophage Colony Stimulating Factor,”Nature, 309:763-767 (1984).
Grabbe, J. et al., “Stem Cell Factor, a Novel Cutaneous Growth Factor for Mast Cells and Melanocytes,”Arch. Dermatol. Res.,287:78-84 (1994).
Hiraoka et al., “Further Characterization of the Biological Properties of Human Hematopoietic Survival and Growth Factor,”Expl. Cell. Biol.,57:27-34 (1989).
Hiraoka et al., “Production of Human Hematopoietic Survival and Growth Factor by a Myeloid Leukemia Cell Line (KPB-M15) and Placenta as Detected by a Monoclonal Antibody,”Cancer Research, 47:5025-5030 (1987).
Hiraoka et al., “Human Hematopoietic Survival and Growth Factor,”Cell Biology International Reports, 10(5):347-355 (1986).
Hiraoka et al., “Monoclonal Antibodies Against Human Hematopoietic Survival and Growth Factor,”Biomed. Biochim. Acta, 46(5):419-427 (1987).
Hiraoka et al., “In Vitro Effect of Murine Peritonela Exudate Cells Activated with a Streptococcal Preparation, OK-432, on Hematopoietic Stem Cells,”ACTA Hematol. Japan, 45:82-90 (1982).
Hiraoka et al., Cancer Research, 47(19):5025-5030 (1987); A
Bosselman Robert A.
Martin Francis H.
Suggs Sidney V.
Zsebo Krisztina M.
Amgen Inc.
Bunner Bridget E.
Kemmerer Elizabeth
Marshall & Gerstein & Borun LLP
LandOfFree
Method of stimulating growth of melanocyte cells by... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of stimulating growth of melanocyte cells by..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of stimulating growth of melanocyte cells by... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3481702